Douglas Corley to Risk
This is a "connection" page, showing publications Douglas Corley has written about Risk.
Connection Strength
0.411
-
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 Apr 03; 370(14):1298-306.
Score: 0.106
-
Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013 Dec 11; 310(22):2435-42.
Score: 0.104
-
Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016 Oct; 17(10):1363-1373.
Score: 0.031
-
Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma. Cancer Med. 2016 09; 5(9):2657-65.
Score: 0.031
-
Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer. 2016 Mar 01; 138(5):1146-52.
Score: 0.030
-
Observational methods to assess the effectiveness of screening colonoscopy in reducing right colon cancer mortality risk: SCOLAR. J Comp Eff Res. 2015 Nov; 4(6):541-51.
Score: 0.029
-
Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. JAMA. 2015 Jun 16; 313(23):2349-58.
Score: 0.029
-
Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. Gastroenterology. 2015 Feb; 148(2):367-78.
Score: 0.028
-
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012 Aug; 143(2):336-46.
Score: 0.023